Experts
    • Internal Medicine
    • Hematology and Oncology
    • Professor in the Dept of Medicine (Division of Oncology) and Urology at University of Washington
    Dr. Higano is a Professor in the Departments of Medicine (Division of Oncology) and Urology at the University of Washington and is a Member of the Clinical Division at Fred Hutchinson Cancer Research Center. She graduated from University of Massachusetts Medical School and trained in Internal Medicine at the Mayo Clinic in Rochester, Minnesota. She completed a fellowship in hematology/oncology at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Higano conducts clinical/translational research in prostate cancer. Her group has been directly involved in the development of sipuleucel-T, abiraterone, and enzalutamide and she is a global principal investigator on several phase 3 trials. Her own research focus has been on using intermittent androgen suppression to study the side effects of androgen deprivation therapy. Dr. Higano has been the Oncology Discipline Chair on the Genitourinary Oncology Committee of the Southwest Oncology Group since 1993. She has had many roles in the American Society of Clinical Oncology over the years including serving on the Scientific Program and Education Committees and was a candidate for the Nominating Committee. She is a member of the National Comprehensive Cancer Networks Prostate Cancer Guideline Committee. She has been on numerous editorial boards including the Journal of Clinical Oncology. She is the University of Washington PI for the Department of Defense Prostate Cancer Clinical Trials Consortium and was the Clinical Core Director for the Pacific Northwest SPORE program from 2002-2012.
    • Medical Oncology
    • Professor of Medicine, Division of Oncology and Urology at University of Washington
    Dr. Montgomery is Professor of Medicine in the Division of Oncology and Urology at the University of Washington. He graduated from Dartmouth College and Duke Medical School and completed his residency in internal medicine at Brigham and Women’s Hospital, Harvard Medical School. He completed fellowship in Oncology at University of Washington and Fred Hutchinson Cancer Research Center. Dr. Montgomery carries out translational research in prostate and bladder cancer with a focus on tissue based analysis of androgen metabolism and mechanisms of resistance to androgen receptor targeting and platinum chemotherapy. He has designed and completed a broad range of phase I-III studies in localized and metastatic prostate cancer. Dr. Montgomery has served on multiple editorial boards, including the Journal of Clinical Oncology, program committees for national meetings and serves as clinical director of genitourinary oncology at University of Washington, and Seattle Cancer Care Alliance.
  • Dr. Christopher Barbieri is a urologic oncologist and Assistant Professor of Urology and Assistant Professor of Cell and Developmental Biology at Weill Cornell Medical College. Prior to coming onboard at Weill Cornell Medical College/New York-Presbyterian Hospital, he received his undergraduate degree from Dartmouth College and then attended Vanderbilt University School of Medicine, where he obtained both his MD and PhD degrees. He then completed Urology Residency and Urologic Oncology Fellowship at Weill Cornell. Dr. Barbieri’s research interests include using genomic data to define distinct molecular subclasses of urological malignancy, with a particular focus on prostate cancer. His work has led to recognition as a Prostate Cancer Foundation Young Investigator and a Urology Care Foundation Research Scholar; he is also the recipient of a Career Development Award from the National Cancer Institute to fund his work on prostate cancer.
    • Cancer Genomics
    • Prostate Cancer
    • Computatioanl Biology
    • Associate Professor of Computational Oncology at University of Trento
    Francesca Demichelis, PhD, is expert in the area of Cancer Genomics. Dr. Demichelis’ research group at the Centre for Integrative Biology at the University of Trento, Italy, focuses on the characterization of tumor evolution and progression through the study of intra- and inter-tumor heterogeneity. Using single base level information from tissue biopsies or circulating DNA (plasma), tumor dynamics and evolution maps are charted to inform on patient’s status and treatment response. Dr. Demichelis also studies the impact of inherited polymorphisms, including structural variants, within transcriptionally active regulatory regions of the genome on the initiation of hormone regulated cancer phenotypes. The research group is involved in consortia studies including The Cancer Genome Atlas (TCGA) and Stand Up 2 Cancer International/ PCF Dream Team. Dr. Demichelis has received support from the European Research Council (ERC), Department of Defense (USA), and the National Cancer Institute (NCI).
    • Medical Oncology
    Medical Oncologist, Memorial Sloan Kettering Cancer Center
    Medical Oncologist, Memorial Sloan Kettering Cancer Center
    I am Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering and a board-certified medical oncologist with special expertise in treating men with advanced prostate cancer. Under my leadership, the Genitourinary Oncology Service program is dedicated to the treatment of prostate cancer, testicular cancer, bladder and upper-tract urothelial cancer, and kidney cancer. Our objective is to foster synergy between scientific research and clinical practice, and to ensure that promising scientific discoveries are used to develop new diagnostic tests and treatments for patients. My own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic. Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy. As a member of the Prostate Cancer Clinical Trials Working Group, I led an international effort to standardize development of the design, conduct, and analysis of phase 2 clinical trials in prostate cancer, so we can better evaluate new therapeutics and assess their effectiveness using novel imaging modalities. The recommendations were incorporated and contributed to the successful development of zytiga (now approved) and enzalutamide (under review by the FDA). Both of these agents target androgen receptor signaling and were shown to prolong the survival of men with castration-resistant disease. I also developed the Clinical States Model of Prostate Cancer Progression, which, in categorizing the clinical spectrum of prostate cancer from diagnosis to metastasis, provides a framework to access and reassess a patient’s prognosis as the disease evolves over time and to guide management of the disease. I am also the principal investigator of the Memorial Sloan Kettering Prostate Cancer SPORE (Specialized Program on Research Excellence) sponsored by the National Cancer Institute and Principal Investigator of the Prostate Cancer Clinical Trials Consortium, a 13-center research collaborative headquartered at Memorial Sloan Kettering and funded by the Department of Defense and the Prostate Cancer Foundation. A critical part of this effort is to design and conduct clinical trials of promising new approaches so that they are available to patients as soon as possible. Since 2006, the consortium has facilitated more than 120 new early-phase studies related to prostate cancer. Ultimately, through these clinical trials, we seek to develop more-effective treatments for prostate cancers of all stages and to discover means of prevention. In addition to serving as Chief of the Genitourinary Oncology Service for the past 16 years, I am the incumbent of the D. Wayne Calloway Chair in Urologic Oncology and a Professor of Medicine at the Weill Cornell Medical College. I am a recipient of the Donald S. Coffey-Prostate Cancer Foundation Physician-Scientist Award, and the Distinguished Alumnus Award. I also serve on numerous editorial and scientific advisory boards and am a reviewer for many journals, including The New England Journal of Medicine, Nature, Science and Translational Medicine, Lancet Oncology, and the Journal of Clinical Oncology. I have written extensively and published over 490 peer-reviewed articles in scientific journals and coauthored the textbook Principals and Practice of Genitourinary Oncology.
  • Lance Hampton is a urologist at VCU Health and the chairman of urology, an associate professor of surgery and the Barbara and William Thalhimer Professor of Urology at Virginia Commonwealth University. Dr. Hampton is also the co-director of the Urologic Tumor Clinic at VCU Massey Cancer Center, where he directs a multidisciplinary prostate cancer program and has treated thousands of prostate cancer patients at all stages of their disease. After graduating from Texas Tech University Medical School, Dr. Hampton completed a residency in general surgery and urology from the University of New Mexico. After several years as the managing partner of Northern Arizona Urology, LLC, he completed a fellowship in Urologic Oncology and Robotic Surgery at the City of Hope National Medical Center in Duarte, California. While at VCU, Dr. Hampton has been the Director of Robotic Surgery and has presided over the rapid expansion of robotic surgery for all urologic malignancies. He has been an invited speaker regarding robotic surgery and urologic malignancy in the US, Europe, and Asia. He has a particular interest in urologic care in Vietnam and has travelled there extensively teaching and demonstrating advanced minimally-invasive techniques. Dr. Hampton's research interests include: advanced techniques for urologic malignancy, development of educational courses for advanced robotic surgery, and the use of social media in urologic training programs.